Strik, Herwig Matthias

[["dc.bibliographiccitation.firstpage","226"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Folia Neuropathologica"],["dc.bibliographiccitation.lastpage","233"],["dc.bibliographiccitation.volume","52"],["dc.contributor.author","Kallenberg, Kai"],["dc.contributor.author","Goldmann, Torben"],["dc.contributor.author","Menke, Jan"],["dc.contributor.author","Strik, Herwig"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Mohr, Alexander"],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Frahm, Jens"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Knauth, Michael"],["dc.date.accessioned","2018-11-07T09:45:46Z"],["dc.date.available","2018-11-07T09:45:46Z"],["dc.date.issued","2014"],["dc.description.abstract","Introduction: Malignant brain tumors tend to migration and invasion of surrounding brain tissue. Histopathological studies reported malignant cells in macroscopically unsuspicious parenchyma (normal appearing white matter - NAWM) remote from the tumor localization. In early stages, diffuse interneural infiltration with changes of the apparent diffusion coefficient (ADC) and fractional anisotropy (FA) is hypothesized. Material and methods: Patients' ADC and FA values from NAWM of the hemisphere contralateral to a malignant glioma were compared to age- and sex-matched normal controls. Results: Apparent diffusion coefficient levels of the entire contra lateral hemisphere revealed a significant increase and a decrease of FA levels. An even more pronounced ADC increase was found in a region mirroring the glioma location. Conclusions: In patients with previously untreated anaplastic astrocytoma or glioblastoma, an increase of the ADC and a reduction of FA were found in the brain parenchyma of the hemisphere contralateral to the tumor localization. In the absence of visible MRI abnormalities, this may be an early indicator of microstructural changes of the NAWM attributed to malignant brain tumor."],["dc.description.sponsorship","Volkswagen Stiftung [ZN1635, ZN 2193]"],["dc.identifier.doi","10.5114/fn.2014.45563"],["dc.identifier.isi","000342712000002"],["dc.identifier.pmid","25310733"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34702"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1509-572X"],["dc.relation.issn","1641-4640"],["dc.title","Abnormalities in the normal appearing white matter of the cerebral hemisphere contralateral to a malignant brain tumor detected by diffusion tensor imaging"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","295"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Experimental and Therapeutic Medicine"],["dc.bibliographiccitation.lastpage","299"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Brunotte, J."],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Hemmerlein, Bernhard"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.date.accessioned","2018-11-07T08:58:36Z"],["dc.date.available","2018-11-07T08:58:36Z"],["dc.date.issued","2011"],["dc.description.abstract","Erythropoietin (EPO) is used to treat anemia in neoplastic disease. EPO also exerts neuroprotective effects on neuronal cells, making a prophylactic use against the neurocognitive effects of radiochemotherapy probable. However, EPO/EPO-receptor (EPOR) signalling has been also detected in glioblastoma cells. Data collected in vitro and in vivo show conflicting results on the effect of EPO on malignant gliomas. The association between EPO and EPOR expression and the prognosis of human glioblastomas was analyzed. Probes of human glioblastomas with complete documentation of clinical course and treatment were assessed by immunohistochemistry for the expression of EPO and EPOR (n=80). Using univariate and multivariate survival analysis, the association with age, gender, radiation, chemotherapy and extent of resection was determined. High levels of EPOR were correlated with a median survival advantage of 7 months (p<0.01). By univariate, but not multivariate, analysis, high levels of EPO and EPOR were associated with a significant prolongation of 7 months median survival when compared to low levels of both molecules. In patients treated with radiochemotherapy adjuvant to surgery, the median survival was 6.5 months longer in patients with high levels of EPOR (p<0.04). According to previous studies, longer patient survival is associated with EPOR expression. Therefore, EPO appears to be safe for the treatment of anemia in glioblastoma patients. However, a prophylactic use, i.e., for neuroprotection, is not recommended in light of the functional studies described in the literature."],["dc.identifier.doi","10.3892/etm.2011.198"],["dc.identifier.isi","000287822700019"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23680"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Spandidos Publ Ltd"],["dc.relation.issn","1792-0981"],["dc.title","High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Marosi, Christine"],["dc.date.accessioned","2018-11-07T08:56:08Z"],["dc.date.available","2018-11-07T08:56:08Z"],["dc.date.issued","2011"],["dc.identifier.isi","000208880301300"],["dc.identifier.pmid","28019877"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23067"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Use of Tegwondo, a near-continuous temozolomide regimen, in high- and low-grade gliomas."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","863"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Molecular Medicine Reports"],["dc.bibliographiccitation.lastpage","867"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.contributor.author","Buhk, J.-H."],["dc.contributor.author","Wrede, Arne"],["dc.contributor.author","Hoffmann, A. L."],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Christmann, M."],["dc.contributor.author","Kaina, Bernd"],["dc.date.accessioned","2018-11-07T11:09:39Z"],["dc.date.available","2018-11-07T11:09:39Z"],["dc.date.issued","2008"],["dc.description.abstract","Treatment of recurrent malignant glioma, which has a poor patient prognosis, has not been standardised. Moreover, it is unclear whether repeated treatment with temozolomide is effective in patients who received previous temozolomide treatment before developing a recurrence. Here, we present the results of a high-dose individually adapted 21-day regimen demonstrating that rechallenge is effective even in patients expressing O(6)-methylguanine-DNA methyltransferase (MGMT) in the tumor. Twenty-one patients with recurrent malignant gliomas pre-treated with temozolomide, 18 WHO IV glioblastoma (GBM) and 3 WHO III patients, received 100 mg/m(2) temozolomide on days 1-21/28. The GBM patients had a median Karnofsky performance status of 60% and a median age of 54.8 years. Blood counts decreased continuously, enabling a gradual dose adaptation. When blood counts dropped below normal values, temozolomide was applied on days 1-5/7. Dosage was reduced to 50-75 mg/m(2) in 11 patients and gradually increased up to 130 mg/m(2) in 3 patients. WHO grade 3/4 toxicity was hematological in 3 patients and non-hematological in 3 patients. In GBM patients (n=18), response after >3 months was complete in 3 patients, partial in 1 (22%), stable disease in 7 (39%) and progressive disease in 7 (39%). Progression-free survival at 6 months (PFS-6M) was 39%. Median survival was 9.1 months from relapse and 17.9 months overall. Of the patients with unmethylated MGMT promoter, 2/7 were progression-free for >6 (15 and 19) months. The data indicate that rechallenge with near-continuous, higher-dose temozolomide (100 mg/m(2) on days 1-21/28 or days 1-5/7 with individual dose adaptation) is also feasible in patients with critical blood counts. Objective responses can be achieved even after relapse during a conventional 5/28-day regimen. The resistance of tumors"],["dc.description.sponsorship","[DFG-KA724]"],["dc.identifier.doi","10.3892/mmr_00000042"],["dc.identifier.isi","000261058300016"],["dc.identifier.pmid","21479498"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53056"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Spandidos Publ Ltd"],["dc.relation.issn","1791-2997"],["dc.title","Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","217"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Neuro-Oncology"],["dc.bibliographiccitation.lastpage","222"],["dc.bibliographiccitation.volume","112"],["dc.contributor.author","Kallenberg, Kai"],["dc.contributor.author","Goldmann, Torben"],["dc.contributor.author","Menke, Jan"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Stockhammer, Florian"],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Frahm, Jens"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Knauth, Michael"],["dc.date.accessioned","2018-11-07T09:26:42Z"],["dc.date.available","2018-11-07T09:26:42Z"],["dc.date.issued","2013"],["dc.description.abstract","The most frequent primary brain tumors, anaplastic astrocytomas (AA) and glioblastomas (GBM): tend to invasion of the surrounding brain. Histopathological studies found malignant cells in macroscopically unsuspicious brain parenchyma remote from the primary tumor, even affecting the contralateral hemisphere. In early stages, diffuse interneural infiltration with changes of the apparent diffusion coefficient (ADC) and fractional anisotropy (FA) is suspected. The purpose of this study was to investigate the value of DTI as a possible instrument of depicting evidence of tumor invasion into the corpus callosum (CC). Preoperatively, 31 patients with high-grade brain tumors (8 AA and 23 GBM) were examined by MRI at 3 T, applying a high-resolution diffusion tensor imaging (DTI) sequence. ADC- and FA-values were analyzed in the tumor-associated area of the CC as identified by fiber tracking, and were compared to matched healthy controls. In (MR-)morphologically normal appearing CC the ADC values were elevated in the tumor patients (n = 22; 0.978 x 10(-3) mmA(2)/s) compared to matched controls (0.917 x 10(-3) mmA(2)/s, p < 0.05), and the corresponding relative FA was reduced (rFA: 88 %, p < 0.01). The effect was pronounced in case of affection of the CC visible on MRI (n = 9; 0.978 x 10(-3) mmA(2)/s, p < 0.05; rFA: 72 %, p < 0.01). Changes in diffusivity and anisotropy in the CC can be interpreted as an indicator of tumor spread into the contralateral hemisphere not visible on conventional MRI."],["dc.description.sponsorship","Volkswagen Stiftung [ZN1635, ZN 2193]"],["dc.identifier.doi","10.1007/s11060-013-1049-y"],["dc.identifier.isi","000316755000009"],["dc.identifier.pmid","23344787"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10366"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30361"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0167-594X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Glioma infiltration of the corpus callosum: early signs detected by DTI"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","805"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Radiology"],["dc.bibliographiccitation.lastpage","812"],["dc.bibliographiccitation.volume","253"],["dc.contributor.author","Kallenberg, Kai"],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Helms, Gunther"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Wrede, Arne"],["dc.contributor.author","Buhk, Jan-Hendrik"],["dc.contributor.author","Giese, Alf"],["dc.contributor.author","Frahm, Jens"],["dc.contributor.author","Strik, Herwig"],["dc.contributor.author","Dechent, Peter"],["dc.contributor.author","Knauth, Michael"],["dc.date.accessioned","2018-11-07T11:21:46Z"],["dc.date.available","2018-11-07T11:21:46Z"],["dc.date.issued","2009"],["dc.description.abstract","Purpose: To use localized in vivo proton magnetic resonance (MR) spectroscopy of the contralateral hemisphere in patients with glioblastoma multiforme (GBM) to detect alterations in cerebral metabolites as potential markers of infiltrating GBM cells. Materials and Methods: The study was approved by the ethics committee, and written informed consent was obtained. Twenty-two patients with newly diagnosed and untreated GBM underwent in vivo single-voxel short echo time proton MR spectroscopy with a 3-T MR imaging system. Absolute metabolite concentrations in the hemisphere contralateral to the tumor were compared with data from five patients with low-grade gliomas (LGGs) and from a group of 14 age-matched control subjects by using analysis of variance and subsequent t tests or corresponding nonparametric tests. Results: In the contralateral hemisphere, MR spectroscopy revealed increased concentrations of myo-inositol and glutamine. Mean myo-inositol levels were significantly increased in patients with GBM (3.6 mmol/L +/- 0.8 [standard deviation]) relative to levels in control subjects (3.1 mmol/L +/- 0.6; P = .03) and tended to be higher relative to levels in patients with LGG (2.7 mmol/L +/- 0.8; P = .09). Mean glutamine concentrations in patients with GBM (3.4 mmol/L +/- 0.9) differed significantly from those in control subjects (2.7 mmol/L +/- 0.7; P < .01); mean concentrations in patients with GBM differed from those in patients with LGG (2.4 mmol/L +/- 0.5; P < .01). There were no significant differences between data in patients with LGG and in control subjects. Conclusion: Increased concentrations of myo-inositol and glutamine in the contralateral normal-appearing white matter of GBM patients are consistent with mild astrocytosis and suggest the detectability of early neoplastic infiltration by using proton MR spectroscopy in vivo. (C) RSNA, 2009"],["dc.identifier.doi","10.1148/radiol.2533071654"],["dc.identifier.isi","000272247300028"],["dc.identifier.pmid","19789222"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6268"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55854"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Radiological Soc North America"],["dc.relation.issn","0033-8419"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Untreated Glioblastoma Multiforme: Increased Myo-inositol and Glutamine Levels in the Contralateral Cerebral Hemisphere at Proton MR Spectroscopy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Brunotte, J."],["dc.contributor.author","Bock, Hans-Christoph"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Hemmerlein, Bernhard"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.date.accessioned","2018-11-07T08:40:03Z"],["dc.date.available","2018-11-07T08:40:03Z"],["dc.date.issued","2010"],["dc.format.extent","31"],["dc.identifier.isi","000281184800116"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19137"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.publisher.place","Cary"],["dc.relation.conference","9th Meeting of European-Association-of-NeuroOncology"],["dc.relation.eventlocation","Maastricht, NETHERLANDS"],["dc.relation.issn","1522-8517"],["dc.title","EPO AND EPOR IN HUMAN GLIOBLASTOMA: FRIEND OR FOE?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]